23. EFFICACY, SAFETY AND ECONOMIC EVALUATION OF SUBCUTANEOUS RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PATIENTS WITH NON-HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW. YHCĐ. 2024;65(CĐ 12 - Bệnh viện Thủ Đức). doi:10.52163/yhc.v65iCD12.1833